medRxiv 预印本 · 2026-10-23 · 预印本
Developing novel disease therapies is challenging, especially for central nervous system (CNS) disorders, which have a clinical approval rate of 6.2%. Genetic evidence is associated with higher success rates in drug development, but systematically translating genome-wide association study (GWAS) signals into actionable therapeutic hypotheses remains difficult. Here, we present DRUGSETS, a framework that tests whether…
(中文解读待补写)
🔗 打开原文
Bell, N. Y., Uffelmann, E., van Walree, E. 等
本文摘自《每日前沿研究简报 · 2026-10-25》「医学与健康」。本内容仅用于研究信息整理与科普交流,不构成医疗建议。

发表评论 取消回复